Increased incidence of genetic and chronic diseases to promote growth

Dublin, May 25, 2023 /PRNewswire/ — Regenerative Medicine Market – Forecasts 2022-2027 report added of Recruitment.



The regenerative medicine market is estimated to be valued as follows: US$19,322 million in 2020.

companies mentioned

Regenerative treatments and medicines work internally to repair damaged body tissues and organs. These drugs repair damaged body organs that cannot be repaired naturally. This is a process known as rejuvenation. Regenerative medicine can also be used to replace damaged cells, tissues, or organs using healthy cells, tissues, or organs from dead or healthy donors.

A second method of using these agents to repair damaged tissue involves the transfer, or regeneration, of healthy cells or tissue to diseased or damaged cells in order to maintain normal functioning of the body. It includes a process known as

Increase in percentage of genetic and chronic diseases to boost market

Rise in diseases such as Duchenne muscular dystrophy (DMD), Parkinson’s disease, congestive heart failure, and myocardial infarction have increased the demand for cell therapy in the regenerative medicine industry. In addition, market expansion is driven by the use of heterotopic autografts such as bowel, colon and stomach for bladder, ureter and urethral reconstruction.

Many companies are collaborating with other companies and research institutes to advance cell therapy. Government funding for regenerative medicine research is expected to increase, which is one of the major factors driving the market expansion. Moreover, the growing pipeline of regenerative medicine treatments and rising product approvals will further increase the potential for market expansion in the coming years.

by geography

The regenerative medicine market is geographically segmented as follows: North America, south america, Europe, middle east and Africaand Asia Pacific. The largest market share equates to the North America region, owing to the expanding healthcare sector and increasing adoption of stem cell therapy.

Major progress:

  • June 2022: According to headline results published by GSK plc, the PERLA phase II trial demonstrated an objective response rate ( ORR) primary endpoint was achieved. The trial compared dostarimab plus chemotherapy with pembrolizumab plus chemotherapy (NSCLC) in first-line patients with metastatic non-squamous non-small cell lung cancer. The PERLA Phase II trial is the largest global head-to-head trial of a programmed death receptor-1 (PD-1) inhibitor in this cohort, randomized, double-blind, enrolling 243 patients Experiment. In addition, GSK is moving two of his sections of his COSTAR Lung exam into Phase III. Given that the study complied with the protocol-required extension criteria of the Independent Data Oversight Board, the decision was made on its advice. The COSTAR lung phase III trial is a randomized, open-label, three-arm trial in patients with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy and chemotherapy. Covolimab, an investigational selective anti-TIM-3 monoclonal antibody, plus dostarlimab plus docetaxel versus dostarlimab plus docetaxel versus docetaxel alone.

Products offered:

  • BLENREP: BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite early treatment with immunomodulators, proteasome inhibitors, and anti-CD38 antibodies. BLENREP is GSK’s seventh pivotal drug to be approved in 2020. Adult patients with relapsed or resistant multiple myeloma who have received at least four prior therapies, including anti-CD38 monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, are eligible for BLENREP. (belantamab mafodotin-blmf) as monotherapy. Based on response rate, this indication is approved under accelerated approval. Confirmation and description of clinical benefit in confirmatory studies may be a requirement for continued approval of this indication. The anti-BCMA (B cell maturation antigen) drug BLENREP is the first of its kind to be approved globally.

  • ZYNTEGLO: ZYNTEGLO is a one-time gene therapy for patients with beta-thalassemia, commonly known as severe beta-thalassemia or Cooley’s anemia, who require frequent blood transfusions. Mutations in the beta-globin gene cause the body to produce little or no beta-globin, causing beta-thalassemia. Each patient receives a unique formulation of ZYNTEGLO that integrates a functional copy of the betaglobin gene into their own blood stem cells. As a result, patients can produce enough hemoglobin to avoid the need for frequent blood transfusions.

Market segmentation:

By type

By use

  • cardiovascular

  • oncology

  • Dermatology

  • musculoskeletal system

  • others

By end user

  • hospital

  • Biomedical Research Institute

  • research center

For more information on this report, please visit

About is the world’s leading source of international market research reports and market data. It provides up-to-date data on international and regional markets, key industries, top companies, new products and latest trends.

Media contact:

research and market
Laura WoodSenior Manager

For Eastern Standard Time office hours, please call +1-917-300-0470.
US/Canada Toll Free +1-800-526-8630
For GMT office hours, please call +353-1-416-8900.

US Fax: 646-607-1907
Fax (outside US): +353-1-481-1716




View original content: to-boost-grow-301834813.html

Source Research and Market

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *